COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,844 Articles (22,553 medRxiv, 8,291 bioRxiv)

Most recent first Previous |  Page 432: Articles 4311-4320  | Next

SARS-CoV-2 post-vaccine surveillance studies in Australian children and adults with cancer: SerOzNET Quality of Life, Toxicity and Vaccine Beliefs Substudy Statistical Analysis Plan
Donoghue, M. W., Body, A. L., Wakefield, C., Ahern, E. S., Segelov, E.
10.1101/2023.02.28.23286595 — Posted: 2023-03-03
Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease
Flynn, J. M., Huang, Q. Y. M., Zvornicanin, S. N., Schneider-Nachum, G., Shaqra, A. M., Kurt Yilmaz, N., Moquin, S. A., Dovala, D., Schiffer, C. A., Bolon, D. N. A.
10.1101/2023.03.02.530652 — Posted: 2023-03-02
Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
Woo, H. G., Masaud, S.
10.1101/2023.03.01.530717 — Posted: 2023-03-02
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment.
Focosi, D., McConnell, S., Sullivan, D. J., Casadevall, A.
10.1101/2023.03.02.23286677 — Posted: 2023-03-02
The impact of early anti-SARS-CoV-2 antibody production on the length of hospitalization stay among COVID-19 patients
de Almeida, D. V., Cezar, P. A., Fernandes, T. F. B., Schwarz, M. G. A., Mendonca-Lima, L., Giacoia-Gripp, C. B. W., Cortes, F. H., Lindenmeyer Guimaraes, M., Pilotto, J. H., de Sa, N. B. R., Cazote, A. d. S., Gomes, L. R., Quintana, M. d. S. B., Ribeiro-Alves, M., Coelho, L. E., Geraldo, K. M., Ribeiro, M. P. D., Cardoso, S. W., Grinsztejn, B. G. J., Santos, V. G. V. d., Morgado, M. G.
10.1101/2023.03.02.23286693 — Posted: 2023-03-02
A novel approach for estimating vaccine efficacy for infections with multiple disease outcomes: application to a COVID-19 vaccine trial
Williams, L. R., Voysey, M., Pollard, A. J., Grassly, N. C.
10.1101/2023.03.02.23286698 — Posted: 2023-03-02
Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study
Cousins, H. C., Altman, R. B.
10.1101/2023.02.28.23286515 — Posted: 2023-03-02
Use of a digital application to enhance communication and triage between care homes and National Health Service community services in the United Kingdom: a qualitative evaluation
Russell, S., Stocker, R., Cockshott, Z., Mason, S. M., Knight, J., Preston, N., Hanratty, B.
10.1101/2023.03.02.23286669 — Posted: 2023-03-02
COVID-19 or seasonal influenza? How to distinguish in people younger than 65 years old: A retrospective observational cohort study comparing the 2009 pandemic influenza A H1N1 with 2022 SARS-CoV-2 Omicron BA.2 outbreaks in China.
Zhong, W., Wu, Y., Yue, W., Fang, J., Xie, B., Xu, N., Lin, M., Zhu, X., Su, Z., Chen, Y., Li, H., Li, H.
10.1101/2023.02.28.23286466 — Posted: 2023-03-01
SARS-CoV-2 post-vaccine surveillance studies in Australian children and adults with cancer: SerOzNET Statistical Analysis Plan
Body, A. L., Martin, C., Busija, L., Lal, L., Ahern, E. S., MacIntyre, R. C., Segelov, E.
10.1101/2023.02.26.23286261 — Posted: 2023-03-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).